Evidence map›Paper›PMID 41917369›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Treating Immune Thrombotic Thrombocytopenic Purpura with Immunosuppressive Agents.

Konstantine Halkidis

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Konstantine HalkidisDivision of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS, USA. khalkidis@kumc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune thrombotic thrombocytopenic purpura (iTTP) is caused by autoimmune inhibition of the metalloprotease ADAMTS13. Despite recent advances in diagnosis and therapeutics, most patients are treated empirically with a combination of immunosuppression and therapeutic plasma exchange (TPE) while awaiting diagnostic confirmation of the disease. Once diagnosis is confirmed, immunosuppression is continued in both the short and intermediate term to prevent the ongoing acute sequelae of the disease as well as prevent relapse of iTTP. Here, I describe approaches for immunosuppressive therapy in patients with iTTP.

Indexed as

Immunosuppressive AgentsPurpura, Thrombotic ThrombocytopenicADAMTS13 ProteinHumansPlasma ExchangeADAMTS13 ProteinADAMTS13 protein, humanImmunosuppressive AgentsImmunosuppressionProphylaxisSteroidsTherapeutic antibodiesThrombotic thrombocytopenic purpura

Identifiers

PMID41917369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.